HRP20110406T1 - Derivati (r)-4-(heteroaril)feniletila i farmaceutski sastavi koji ih sadrže - Google Patents
Derivati (r)-4-(heteroaril)feniletila i farmaceutski sastavi koji ih sadrže Download PDFInfo
- Publication number
- HRP20110406T1 HRP20110406T1 HR20110406T HRP20110406T HRP20110406T1 HR P20110406 T1 HRP20110406 T1 HR P20110406T1 HR 20110406 T HR20110406 T HR 20110406T HR P20110406 T HRP20110406 T HR P20110406T HR P20110406 T1 HRP20110406 T1 HR P20110406T1
- Authority
- HR
- Croatia
- Prior art keywords
- phenyl
- ethyl
- amino
- trifluoromethyl
- thiazol
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 12
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims abstract 4
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims abstract 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract 2
- 206010016654 Fibrosis Diseases 0.000 claims abstract 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims abstract 2
- 206010034277 Pemphigoid Diseases 0.000 claims abstract 2
- 201000004681 Psoriasis Diseases 0.000 claims abstract 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract 2
- 208000027418 Wounds and injury Diseases 0.000 claims abstract 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims abstract 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims abstract 2
- 230000006378 damage Effects 0.000 claims abstract 2
- 230000004761 fibrosis Effects 0.000 claims abstract 2
- 208000014674 injury Diseases 0.000 claims abstract 2
- 208000028867 ischemia Diseases 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- 230000010410 reperfusion Effects 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 150000003536 tetrazoles Chemical class 0.000 claims 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 3
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 3
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical group C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 3
- 150000003852 triazoles Chemical group 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- -1 C1-C4-acyloxy Chemical group 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 claims 1
- NSRDFEDODHRJJA-SSDOTTSWSA-N 4-[(1r)-1-[4-[[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]phenyl]ethyl]-1,2,5-oxadiazol-3-one Chemical compound C1([C@H](C)C=2C=CC(NC=3SC=C(N=3)C(F)(F)F)=CC=2)=NON=C1O NSRDFEDODHRJJA-SSDOTTSWSA-N 0.000 claims 1
- PWNMDNDIVOXBSU-SSDOTTSWSA-N 4-[(1r)-1-[4-[[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]phenyl]ethyl]-1,2,5-thiadiazol-3-one Chemical compound C1([C@H](C)C=2C=CC(NC=3SC=C(N=3)C(F)(F)F)=CC=2)=NSN=C1O PWNMDNDIVOXBSU-SSDOTTSWSA-N 0.000 claims 1
- RCKAGEAESHXMIH-MRVPVSSYSA-N 4-methyl-5-[(1r)-1-[4-[[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]phenyl]ethyl]-1,2-oxazol-3-one Chemical compound C=1([C@H](C)C=2C=CC(NC=3SC=C(N=3)C(F)(F)F)=CC=2)ON=C(O)C=1C RCKAGEAESHXMIH-MRVPVSSYSA-N 0.000 claims 1
- JZCYGJPMWDIUIJ-MRVPVSSYSA-N 5-[(1r)-1-[4-[[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]phenyl]ethyl]-1,2-oxazol-3-one Chemical compound C1([C@H](C)C=2C=CC(NC=3SC=C(N=3)C(F)(F)F)=CC=2)=CC(O)=NO1 JZCYGJPMWDIUIJ-MRVPVSSYSA-N 0.000 claims 1
- XLIYNKPPYHDVHC-MRVPVSSYSA-N 5-[(1r)-1-[4-[[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]phenyl]ethyl]-1,2-thiazol-3-one Chemical compound C1([C@H](C)C=2C=CC(NC=3SC=C(N=3)C(F)(F)F)=CC=2)=CC(O)=NS1 XLIYNKPPYHDVHC-MRVPVSSYSA-N 0.000 claims 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003622 mature neutrocyte Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- NZXOOPPMMVMGAQ-MRVPVSSYSA-N n-[4-[(1r)-1-(2-hydroxy-1,2,4-triazol-3-yl)ethyl]phenyl]-4-(trifluoromethyl)-1,3-thiazol-2-amine Chemical compound C1([C@H](C)C=2C=CC(NC=3SC=C(N=3)C(F)(F)F)=CC=2)=NC=NN1O NZXOOPPMMVMGAQ-MRVPVSSYSA-N 0.000 claims 1
- HJCSELXWCNTCBX-SNVBAGLBSA-N n-[4-[(1r)-1-(2-hydroxy-4-methylpyrazol-3-yl)ethyl]phenyl]-4-(trifluoromethyl)-1,3-thiazol-2-amine Chemical compound C1([C@H](C)C=2C=CC(NC=3SC=C(N=3)C(F)(F)F)=CC=2)=C(C)C=NN1O HJCSELXWCNTCBX-SNVBAGLBSA-N 0.000 claims 1
- ANJBIEBLHPUZNB-SECBINFHSA-N n-[4-[(1r)-1-(2-hydroxypyrazol-3-yl)ethyl]phenyl]-4-(trifluoromethyl)-1,3-thiazol-2-amine Chemical compound C1([C@H](C)C=2C=CC(NC=3SC=C(N=3)C(F)(F)F)=CC=2)=CC=NN1O ANJBIEBLHPUZNB-SECBINFHSA-N 0.000 claims 1
- OXJPICCVZKNYLU-MRVPVSSYSA-N n-[4-[(1r)-1-(3-hydroxytriazol-4-yl)ethyl]phenyl]-4-(trifluoromethyl)-1,3-thiazol-2-amine Chemical compound C1([C@H](C)C=2C=CC(NC=3SC=C(N=3)C(F)(F)F)=CC=2)=CN=NN1O OXJPICCVZKNYLU-MRVPVSSYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000004913 activation Effects 0.000 abstract 2
- 230000003399 chemotactic effect Effects 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07020396 | 2007-10-18 | ||
| PCT/EP2008/064023 WO2009050258A1 (en) | 2007-10-18 | 2008-10-17 | (r)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110406T1 true HRP20110406T1 (hr) | 2011-06-30 |
Family
ID=40325746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110406T HRP20110406T1 (hr) | 2007-10-18 | 2011-05-31 | Derivati (r)-4-(heteroaril)feniletila i farmaceutski sastavi koji ih sadrže |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8133911B2 (ja) |
| EP (1) | EP2201006B1 (ja) |
| JP (1) | JP5374511B2 (ja) |
| CN (1) | CN101827841B (ja) |
| AT (1) | ATE501140T1 (ja) |
| AU (1) | AU2008313669B2 (ja) |
| BR (1) | BRPI0817824B8 (ja) |
| CA (1) | CA2702307C (ja) |
| DE (1) | DE602008005488D1 (ja) |
| DK (1) | DK2201006T3 (ja) |
| ES (1) | ES2361233T3 (ja) |
| HK (1) | HK1146723A1 (ja) |
| HR (1) | HRP20110406T1 (ja) |
| IL (1) | IL205029A (ja) |
| PL (1) | PL2201006T3 (ja) |
| PT (1) | PT2201006E (ja) |
| RU (1) | RU2475486C2 (ja) |
| SI (1) | SI2201006T1 (ja) |
| WO (1) | WO2009050258A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2166006A1 (en) * | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| EP3498269A1 (en) * | 2017-12-12 | 2019-06-19 | Dompé farmaceutici S.p.A. | C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain |
| CN115433143B (zh) * | 2021-06-03 | 2023-10-13 | 中国科学院大连化学物理研究所 | 一种异噻唑啉酮类化合物的合成方法 |
| EP4397306A1 (en) | 2023-01-05 | 2024-07-10 | Dompe' Farmaceutici S.P.A. | C5ar1 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9710002A (pt) * | 1996-06-27 | 1999-08-10 | Janssen Pharmaceutica Nv | N-[4-(heteroarilmetil)fenil]-heteroarilaminas |
| ITMI20012025A1 (it) * | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
| CA2629935C (en) * | 2005-11-24 | 2016-01-19 | Dompe S.P.A. | (r)-arylalkylamino derivatives and pharmaceutical compositions containing them |
-
2008
- 2008-10-17 ES ES08840589T patent/ES2361233T3/es active Active
- 2008-10-17 DE DE602008005488T patent/DE602008005488D1/de active Active
- 2008-10-17 EP EP08840589A patent/EP2201006B1/en active Active
- 2008-10-17 PL PL08840589T patent/PL2201006T3/pl unknown
- 2008-10-17 BR BRPI0817824A patent/BRPI0817824B8/pt active IP Right Grant
- 2008-10-17 AT AT08840589T patent/ATE501140T1/de not_active IP Right Cessation
- 2008-10-17 JP JP2010529394A patent/JP5374511B2/ja active Active
- 2008-10-17 PT PT08840589T patent/PT2201006E/pt unknown
- 2008-10-17 WO PCT/EP2008/064023 patent/WO2009050258A1/en active Application Filing
- 2008-10-17 CN CN200880112174XA patent/CN101827841B/zh active Active
- 2008-10-17 CA CA2702307A patent/CA2702307C/en active Active
- 2008-10-17 DK DK08840589.9T patent/DK2201006T3/da active
- 2008-10-17 AU AU2008313669A patent/AU2008313669B2/en active Active
- 2008-10-17 RU RU2010119705/04A patent/RU2475486C2/ru active
- 2008-10-17 SI SI200830268T patent/SI2201006T1/sl unknown
- 2008-10-17 US US12/681,841 patent/US8133911B2/en active Active
-
2010
- 2010-04-12 IL IL205029A patent/IL205029A/en active IP Right Grant
-
2011
- 2011-01-27 HK HK11100835.6A patent/HK1146723A1/xx unknown
- 2011-05-31 HR HR20110406T patent/HRP20110406T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0817824B8 (pt) | 2021-05-25 |
| HK1146723A1 (en) | 2011-07-08 |
| DE602008005488D1 (de) | 2011-04-21 |
| BRPI0817824B1 (pt) | 2018-12-26 |
| US20100249198A1 (en) | 2010-09-30 |
| CN101827841B (zh) | 2012-11-28 |
| BRPI0817824A2 (pt) | 2015-03-31 |
| AU2008313669B2 (en) | 2014-01-16 |
| CA2702307A1 (en) | 2009-04-23 |
| PT2201006E (pt) | 2011-05-05 |
| EP2201006A1 (en) | 2010-06-30 |
| EP2201006B1 (en) | 2011-03-09 |
| IL205029A0 (en) | 2010-11-30 |
| US8133911B2 (en) | 2012-03-13 |
| WO2009050258A1 (en) | 2009-04-23 |
| RU2010119705A (ru) | 2011-11-27 |
| AU2008313669A1 (en) | 2009-04-23 |
| JP5374511B2 (ja) | 2013-12-25 |
| SI2201006T1 (sl) | 2011-07-29 |
| PL2201006T3 (pl) | 2011-08-31 |
| ES2361233T3 (es) | 2011-06-15 |
| ATE501140T1 (de) | 2011-03-15 |
| CN101827841A (zh) | 2010-09-08 |
| JP2011500643A (ja) | 2011-01-06 |
| IL205029A (en) | 2014-09-30 |
| RU2475486C2 (ru) | 2013-02-20 |
| DK2201006T3 (da) | 2011-06-27 |
| CA2702307C (en) | 2016-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI222447B (en) | 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents | |
| CA2871007C (en) | Triazolone compounds as mpges-1 inhibitors | |
| IL269196B2 (en) | Heterocyclic glutaminyl cyclase inhibitors, their uses as drugs and pharmaceutical preparations containing them | |
| RU2501791C2 (ru) | Производное триазола или его соль | |
| AU2006242824B2 (en) | Antimicrobial agents | |
| HRP20110406T1 (hr) | Derivati (r)-4-(heteroaril)feniletila i farmaceutski sastavi koji ih sadrže | |
| JP2009524678A5 (ja) | ||
| CZ297907B6 (cs) | Aminothiazolové deriváty a farmaceutické kompozice s jejich obsahem | |
| JP4939226B2 (ja) | チアゾール環を含むカルボン酸誘導体およびその医薬用途 | |
| JP2020512373A5 (ja) | ||
| JP2010513272A5 (ja) | ||
| CA2409697A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| JP2018519323A5 (ja) | ||
| JP2007523905A5 (ja) | ||
| JP2012521405A5 (ja) | ||
| AR103807A1 (es) | Tratamiento de la pancreatitis | |
| KR20020062341A (ko) | 사이클린 의존성 키나제의 아미노티아졸 억제제 | |
| MX2012008280A (es) | Compuestos y metodos. | |
| CA2747419A1 (en) | Sulfonamide derivatives | |
| JP2003534336A5 (ja) | ||
| HRP20191554T1 (hr) | Derivat azol benzena | |
| KR100909953B1 (ko) | 항진균 활성을 갖는 트라이아졸 유도체, 이의 제조방법 및이를 함유하는 약학 조성물 | |
| JP2010540462A5 (ja) | ||
| HRP20200606T1 (hr) | Derivati fenila kao agonisti kanabinoidnog receptora 2 | |
| EP3212642A1 (en) | AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORyT |